BioCentury
ARTICLE | Clinical News

Repros jumps on Phase III Androxal data

August 29, 2014 1:18 AM UTC

Repros Therapeutics Inc. (NASDAQ:RPRX) jumped $3.37 (19%) to $21.58 on Thursday after reporting data from the Phase III ZA-305 trial of Androxal enclomiphene to treat secondary hypogonadism. In the trial, 65.9% of patients receiving Androxal achieved a 24-hour average testosterone level in the normal range with a mean sperm concentration of 10 million/mL or greater -- a co-primary endpoint -- vs. 33.3% for AndroGel 1.62% testosterone gel from AbbVie Inc. (NYSE:ABBV) (p=0.0047) and 7.3% for placebo (p<0.0001).

Androxal led to a 14% increase in mean sperm concentration from baseline to week 16 -- also a co-primary endpoint. The increase was non-significant from baseline, significant compared to a 30% reduction in sperm concentration at week 16 for AndroGel (p=0.0004) and non-significant compared to an increase of 7% for placebo (p=0.2042). ...